June 21, 2021
3 min watch
Save
High treatment costs often unrecognized in AML
Healio spoke with Jonathan M. Gerber, MD, of the Center for Cancer Excellence at the University of Massachusetts Medical School and UMass Memorial Health Care System, and HemOnc Today Editorial Board member, about the underrecognized burden of high treatment costs in AML.
Click here to watch the next video in the series on the clinical implications of the BEAT-AML trial and genetic testing in AML.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Gerber served as a principal investigator on a study funded by Janssen evaluating a CD123 bispecific agent and holds a patent (but has not collected royalties) on a leukemia stem cell detection assay for AML.
Read more about